We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+7.08%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.36B
AUM Growth
-$71M
(-2.9%)
Cap. Flow
-$199M
Cap. Flow
% of AUM
-8.42%
Top 10 Holdings %
Top 10 Hldgs %
44.44%
Holding
74
New
10
Increased
32
Reduced
22
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$49.8M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$19.7M |
| 3 |
RLYP
RELYPSA INC COM
RLYP
|
+$16.9M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$14.6M |
| 5 |
PTC Therapeutics
PTCT
|
+$12.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ironwood Pharmaceuticals
IRWD
|
+$55.6M |
| 2 |
AGN
Allergan Inc
AGN
|
+$47.4M |
| 3 |
Gilead Sciences
GILD
|
+$43.5M |
| 4 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$43.1M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$40.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$30.4B
| $177M | 7.5% |
561,379
+24,986
| +5% | +$7.52M |
|
2
Amgen
AMGN
$198B
| $141M | 5.99% |
1,195,165
-209,897
| -15% | -$24.3M |
|
|
3
Gilead Sciences
GILD
$167B
| $124M | 5.27% |
1,499,116
-558,300
| -27% | -$43.5M |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $107M | 4.55% |
1,250,672
+118,200
| +10% | +$8.99M |
|
5
Vertex Pharmaceuticals
VRTX
$123B
| $102M | 4.33% |
1,079,464
-197,277
| -15% | -$13.8M |
|
6
Incyte
INCY
$23.4B
| $88.7M | 3.76% |
1,571,452
+168,292
| +12% | +$8.59M |
|
7
Teva Pharmaceuticals
TEVA
$37.3B
| $79.3M | 3.36% |
1,512,587
+70,595
| +5% | +$3.61M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
| $76.4M | 3.24% |
489,108
-58,900
| -11% | -$9.3M |
|
9
Viatris
VTRS
$20.1B
| $76.3M | 3.23% |
1,479,982
+89,285
| +6% | +$4.39M |
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $75.7M | 3.21% |
339,450
+45,500
| +15% | +$9.42M |
|
|
11
BioMarin Pharmaceuticals
BMRN
$11.5B
| $72.7M | 3.08% |
1,168,504
+241,098
| +26% | +$14.6M |
|
12
Regeneron Pharmaceuticals
REGN
$70.9B
| $64.4M | 2.73% |
227,900
-79,500
| -26% | -$23.6M |
|
|
KERX
13
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $57.5M | 2.44% |
3,741,656
+204,066
| +6% | +$2.89M |
|
|
SHPG
14
DELISTED
Shire pic
SHPG
| $54.3M | 2.3% |
230,636
-160,561
| -41% | -$27.9M |
|
|
GEVA
15
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $54.1M | 2.29% |
516,445
+51,300
| +11% | +$4.36M |
|
|
NPSP
16
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $52.2M | 2.21% |
1,580,094
+171,365
| +12% | +$4.95M |
|
|
17
Thermo Fisher Scientific
TMO
$198B
| $52M | 2.2% |
440,300
-345,200
| -44% | -$40.6M |
|
18
Innoviva
INVA
$1.6B
| $51.9M | 2.2% |
1,743,188
-554,012
| -24% | -$13.3M |
|
|
19
Perrigo
PRGO
$1.48B
| $51.2M | 2.17% |
+351,368
| New | +$49.8M |
|
20
Illumina
ILMN
$28.2B
| $44.1M | 1.87% |
253,699
+1,850
| +0.7% | +$276K |
|
21
Halozyme
HALO
$9.23B
| $43.4M | 1.84% |
4,389,682
-965,806
| -18% | -$8.19M |
|
|
22
PTC Therapeutics
PTCT
$6.52B
| $40.5M | 1.72% |
1,551,274
+603,372
| +64% | +$12.9M |
|
|
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $39.8M | 1.69% |
1,365,152
+152,907
| +13% | +$3.7M |
|
24
Insmed
INSM
$23.5B
| $39.7M | 1.68% |
1,985,738
+813,617
| +69% | +$12M |
|
|
MNK
25
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $38.5M | 1.63% |
481,564
+28,800
| +6% | +$2.09M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Sectoral Asset Management held 74 positions worth $2.36B, down 2.9% from $2.43B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Sectoral Asset Management withdrew a net $199M in Q2 2014, closing 10 positions and reducing 22 holdings. Its most notable exit was Aegerion Pharmaceuticals, an estimated $43.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 93% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in Perrigo worth $51.2M.
- Sectoral Asset Management's largest Q2 2014 buy was Perrigo: 351,368 shares worth $51.2M.
- Sectoral Asset Management added most to BioMarin Pharmaceuticals in Q2 2014, an estimated $14.6M increase.
- Sectoral Asset Management's biggest Q2 2014 reduction was Ironwood Pharmaceuticals, cutting an estimated $55.6M.
- Sectoral Asset Management fully exited Aegerion Pharmaceuticals in Q2 2014, selling an estimated $43.1M.
- Sectoral Asset Management's ten largest holdings make up 44% of its $2.36B portfolio in Q2 2014.
- Sectoral Asset Management opened 10 new positions and closed 10 in Q2 2014.
- Sectoral Asset Management's portfolio value fell 2.9% quarter-over-quarter to $2.36B.
Based on Sectoral Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.